Liver News and Research

RSS

CellCept linked to reduced cancer incidence

A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.

23 Apr 2004

Hepatitis B vaccination for inmates

rrectional settings provide a unique opportunity to offer hepatitis B vaccination to a substantial number of high-risk adults who are willing to be vaccinated and who would not otherwise have access to the preventive medicine, according to a new Brown University study of inmates within the Rhode Island Department of Corrections.

23 Apr 2004

Schering-Plough submits Japanese application for hepatitis C drug

Schering-Plough Corporation has announced that Schering-Plough K.K., the company's subsidiary in Japan, has submitted a New Drug Application (J-NDA) to the Ministry of Health, Labor and Welfare (MHLW) seeking marketing approval for PEG-INTRON(R) (peginterferon alfa-2b) Powder for Injection for use in combination with REBETOL(R) (ribavirin) Capsules for the treatment of chronic hepatitis C.

22 Apr 2004

Scientist discovers why skin turns leathery

“The reason our skin becomes more leathery and thick as we age might be due to a loss of elasticity in the cells,” says Igor Sokolov of Clarkson University, who presented his latest research findings during a session on bio-imaging techniques at the Annual American Physical Society (APS) March meeting in Montreal.

21 Apr 2004

Study suggests that donor livers are not always distributed according to a patient's need

A new study suggests that donor livers are not always distributed according to a patient's need, but may be retained by some organ procurement organizations with smaller waiting lists and transplanted into less sick patients, according to a study in the April 21 issue of The Journal of the American Medical Association (JAMA).

20 Apr 2004

Link between iron regulation and the immune system

Patients with chronic inflammatory disorders, including infections, inflammatory bowel disease, arthritis and cancer, commonly become anemic. The anemia can make them sicker, is sometimes severe enough to require a blood transfusion, and responds only partially to current treatments.

20 Apr 2004

New developments in the treatment of pancreatic cancer

A booster dose of a substance already found in the body appears to be safe and non-toxic for the treatment of pancreatic cancer, and shows signs of arresting pancreatic cancer cell growth in patients, Penn State College of Medicine researchers report.

20 Apr 2004

Preclinical data on Histamine's ability to prevent liver damage

These new results demonstrate the ability of histamine to prevent LPS-induced liver injury in a rodent model by showing efficacy when delivered in a manner mimicking oral administration.

19 Apr 2004

Black women with high blood pressure during pregnancy have higher homocysteine levels

Black women with pregnancy-induced high blood pressure have more homocysteine (an amino acid linked with atherosclerosis) and less folic acid in their blood than white women.

19 Apr 2004

Oral treatment of chronic hepatitis C

Valeant Pharmaceuticals today presented 24-week data from Phase 2 clinical trials of Viramidine, a nucleoside (guanosine) analog Valeant is developing in oral form for the treatment of chronic hepatitis C (HCV) in conjunction with a pegylated interferon.

17 Apr 2004

Mayo Clinic debunks myths cancer myths

Believing cancer myths can be dangerous to your health, because they could prevent you from having the tests and treatments needed to detect and treat cancer.

16 Apr 2004

New gene presents a potent new target for breast cancer therapy

A gene known to promote longevity in animals has now been discovered to encode a tumor suppressor – a protein that helps prevent cancer, according to a study by a team of scientists from The University of Texas M. D. Anderson Cancer Center. The new gene, which was inactivated in two-thirds of patients studied, presents a potent new target for breast cancer therapy, the researchers say.

16 Apr 2004

Citrus soda culprit in patient’s medical mystery

It took a team of medical sleuths at Vanderbilt University Medical Center to get to the bottom of what was causing the 35-year-old to have abnormal blood chemistries during a post-transplant check up.

16 Apr 2004

Drug duo prevents life-threatening condition in children undergoing stem cell transplant

A drug duo appears to be a safe and effective way to prevent a serious condition called graft-versus-host-disease (GVHD) in youngsters undergoing a stem cell transplant

14 Apr 2004

FDA approves advanced malignant melanoma drug

Maxim Pharmaceuticals today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination with interleukin-2 (IL-2), for the treatment of patients with advanced malignant melanoma, has been approved by the U.S. Food and Drug Administration (FDA).

14 Apr 2004

Vitamin C can reduce levels of C-reactive protein, a marker of inflammation and chronic disease

Vitamin C supplements can reduce levels of C-reactive protein, a marker of inflammation and chronic disease risk in humans, according to a new study led by researchers at the University of California, Berkeley.

12 Apr 2004

Natural medication shown to not always be a safe alternative to synthetic medication

The common perception that if medication is natural then it must be safe has recently come under fire from a researh by a Consumer Reports magazine. The consumer publication found a dozen herbal supplements, some banned in Asia, Europe and Canada but widely available in the United States, may cause cancer, kidney or liver damage and even death.

10 Apr 2004

Hepatitis C wonder drug Ribasphere gets approval from FDA

The President and CEO of Three Rivers Pharmaceuticals, Donald J. Kerrish, RPh., stated, “The approval of Ribasphere™ marks a milestone in the treatment of HCV. Ribasphere™ is positioned to break down the economic barriers that have existed for the past decade in treating this chronic and potentially deadly disease.” Traditionally the cost of treatment for HCV can range from $20,000 – $25,000 annually. “Our aim is to bring affordable medicine to all individuals infected with this dreadful disease.” Mr. Kerrish continued.

8 Apr 2004

Alcohol screening can spot addiction

Have you ever felt like you needed a drink? If an occasional cocktail changes into a need, it could mean an alcohol problem. National Alcohol Screening Day is April 8. In cities and towns throughout the United States, screening programs will be offered to help people determine whether they exhibit drinking behaviors that could be signs of alcohol addiction.

7 Apr 2004

Research shows that intense high dose cholesterol lowering drugs result in a major reduction in deaths and severe heart attacks

If you want to increase your chances of living longer, taking cholesterol drugs is an easy way to do it. That's the message from a Harvard study of 4,162 people hospitalized in 350 places in eight countries. It is the first research to show that intense lowering of cholesterol results in a major reduction in deaths and severe heart attacks.

7 Apr 2004